• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎的非甾体局部治疗

Nonsteroidal Topical Therapy for Atopic Dermatitis.

作者信息

Del Rosso James Q

机构信息

Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas, Nevada; is with Thomas Dermatology in Las Vegas, Nevada, and is an adjunct clinical professor of dermatology at Touro University Nevada in Henderson, Nevada.

出版信息

J Clin Aesthet Dermatol. 2020 May;13(5):44-48. Epub 2020 May 1.

PMID:32802256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7380691/
Abstract

The author provides a thorough review of the latest topical treatment approaches for atopic dermatitis. Some agents are currently available in the marketplace, while others are in development. Modes of action, including phosphodiesterase-4 inhibition, aryl hydrocarbon receptor activation, and Janus kinase inhibition are discussed. Emphasis is placed on therapeutic approaches related to modes of action, with clinical data included.

摘要

作者全面回顾了特应性皮炎的最新局部治疗方法。一些药物目前已在市场上有售,而其他药物仍在研发中。文中讨论了其作用方式,包括磷酸二酯酶-4抑制、芳烃受体激活和 Janus 激酶抑制。重点介绍了与作用方式相关的治疗方法,并纳入了临床数据。

相似文献

1
Nonsteroidal Topical Therapy for Atopic Dermatitis.特应性皮炎的非甾体局部治疗
J Clin Aesthet Dermatol. 2020 May;13(5):44-48. Epub 2020 May 1.
2
[Development of new topical substances for the treatment of atopic dermatitis].[用于治疗特应性皮炎的新型局部用物质的研发]
Dermatologie (Heidelb). 2022 Jul;73(7):514-519. doi: 10.1007/s00105-022-05005-5. Epub 2022 May 19.
3
Anti-inflammatory topical medication - new developments in the treatment of atopic dermatitis.抗炎外用药物——特应性皮炎治疗的新进展。
Allergol Select. 2021 Aug 27;5:260-264. doi: 10.5414/ALX02255E. eCollection 2021.
4
Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.2%克立硼罗外用软膏:一种用于治疗特应性皮炎的非甾体类、外用、抗炎磷酸二酯酶4抑制剂,正处于临床开发阶段。
J Drugs Dermatol. 2016 Apr;15(4):390-6.
5
The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis.《秀必须继续:新型药物治疗特应性皮炎的临床经验和临床研究更新》。
Curr Opin Allergy Clin Immunol. 2020 Aug;20(4):386-394. doi: 10.1097/ACI.0000000000000652.
6
Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis.克立硼罗:一种用于特应性皮炎的新型非甾体局部治疗药物。
J Pharm Technol. 2019 Aug;35(4):172-178. doi: 10.1177/8755122519844507. Epub 2019 Apr 22.
7
Novel Vehicles For Drug Delivery in Atopic Dermatitis: A Narrative Review.特应性皮炎药物递送的新型载体:叙述性综述
Dermatol Pract Concept. 2023 Oct 1;13(4):e2023216. doi: 10.5826/dpc.1304a216.
8
Review of Atopic Dermatitis and Topical Therapies.特应性皮炎与局部治疗综述
J Cutan Med Surg. 2017 May/Jun;21(3):227-236. doi: 10.1177/1203475416685077. Epub 2016 Dec 27.
9
Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.应对特应性皮炎的免疫发病机制:局部和全身治疗的进展
Semin Cutan Med Surg. 2017 Mar;36(2 Suppl 2):S45-S48. doi: 10.12788/j.sder.2017.012.
10
Update on pediatric atopic dermatitis.儿童特应性皮炎的最新进展。
Cutis. 2020 Sep;106(3):143-146. doi: 10.12788/cutis.0077.

本文引用的文献

1
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).克立硼罗用于3至<24月龄轻度至中度特应性皮炎婴儿的安全性、有效性和药代动力学:一项IV期开放标签研究(CrisADe CARE 1)
Am J Clin Dermatol. 2020 Apr;21(2):275-284. doi: 10.1007/s40257-020-00510-6.
2
Epidemiology of major chronic inflammatory immune-related skin diseases in 2019.2019 年主要慢性炎症性免疫相关皮肤疾病的流行病学。
Expert Rev Clin Immunol. 2020 Feb;16(2):155-166. doi: 10.1080/1744666X.2020.1719833. Epub 2020 Jan 28.
3
Emerging Topical and Systemic JAK Inhibitors in Dermatology.皮肤科新兴的局部和系统 JAK 抑制剂。
Front Immunol. 2019 Dec 3;10:2847. doi: 10.3389/fimmu.2019.02847. eCollection 2019.
4
[The aryl hydrocarbon receptor as the target structure for new drugs in psoriasis and atopic dermatitis].[芳烃受体作为银屑病和特应性皮炎新药的靶标结构]
Hautarzt. 2019 Dec;70(12):942-947. doi: 10.1007/s00105-019-04503-3.
5
Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.芳香烃受体在特应性皮炎和银屑病中的作用。
Int J Mol Sci. 2019 Oct 31;20(21):5424. doi: 10.3390/ijms20215424.
6
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.用芦可替尼乳膏(JAK1/JAK2 抑制剂)或曲安奈德乳膏治疗特应性皮炎。
J Allergy Clin Immunol. 2020 Feb;145(2):572-582. doi: 10.1016/j.jaci.2019.08.042. Epub 2019 Oct 17.
7
New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines.针对白细胞介素 4/13 细胞因子的新型特应性皮炎治疗方法。
Ann Allergy Asthma Immunol. 2020 Jan;124(1):28-35. doi: 10.1016/j.anai.2019.10.005. Epub 2019 Oct 14.
8
Off-label studies on tofacitinib in dermatology: a review.托法替布在皮肤科的非标签研究综述
J Dermatolog Treat. 2021 Jun;32(4):399-409. doi: 10.1080/09546634.2019.1673877. Epub 2019 Oct 3.
9
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.克立硼罗与特应性皮炎皮肤生物标志物:一项患者内随机试验。
J Allergy Clin Immunol. 2019 Nov;144(5):1274-1289. doi: 10.1016/j.jaci.2019.06.047. Epub 2019 Aug 13.
10
More from the Pipeline of Clinical Research on SELECTED SYSTEMIC THERAPIES FOR ATOPIC DERMATITIS.更多关于特应性皮炎特定全身治疗的临床研究进展
J Clin Aesthet Dermatol. 2019 May;12(5):49-53. Epub 2019 May 1.